Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

DOI Web Site 被引用文献6件
  • O. Ringdén
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • M. Labopin
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • A. Bacigalupo
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • W. Arcese
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • U.W. Schaefer
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • R. Willemze
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • H. Koc
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • D. Bunjes
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • E. Gluckman
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • V. Rocha
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • A. Schattenberg
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...
  • F. Frassoni
    From the Centre for Allogeneic Stem Cell Transplantation, Huddinge, Sweden; Centre International Greffes de Moelle, Hôpital Saint-Antoine, European Group for Blood and Marrow Transplantation Data Centre, Institut des Cordeliers, and Department of Hematology, Hôpital Saint-Louis, Paris, France; Bone Marrow Transplant Unit, Ospedale San Martino, Genova, and Institute of Hematology, University La Sapienza, Rome, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, and Department of...

抄録

<jats:p> PURPOSE: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS). </jats:p><jats:p> PATIENTS AND METHODS: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival. </jats:p><jats:p> RESULTS: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P < .0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P < .0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P < .0001), promyelocytic leukemia (M3) versus other French-American-British types (P < .0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P < .0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS. </jats:p><jats:p> CONCLUSION: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM. </jats:p>

収録刊行物

被引用文献 (6)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ